CeNeRx is a privately held drug development company searching
for new and innovative medicines to help healthcare providers
and patients enhance positive mental health and conquer
neurological diseases.
Based in North Carolina's Research Triangle Park area, CeNeRx
focuses on identifying and developing promising therapeutics to
treat diseases related to neurotransmitters -- therapeutic priorities
include anxiety, bipolar disorder, dementia, depression, epilepsy,
neuropathic pain, schizophrenia, Parkinson's and Alzheimer's
disease.
CeNeRx currently has a series of compounds known as RIMAs
(reversible inhibitors of monoamine oxidase) in phase I
development for the treatment of Major Depressive Disorder.
for new and innovative medicines to help healthcare providers
and patients enhance positive mental health and conquer
neurological diseases.
Based in North Carolina's Research Triangle Park area, CeNeRx
focuses on identifying and developing promising therapeutics to
treat diseases related to neurotransmitters -- therapeutic priorities
include anxiety, bipolar disorder, dementia, depression, epilepsy,
neuropathic pain, schizophrenia, Parkinson's and Alzheimer's
disease.
CeNeRx currently has a series of compounds known as RIMAs
(reversible inhibitors of monoamine oxidase) in phase I
development for the treatment of Major Depressive Disorder.
Welcome to CeNeRx!
what's new with CeNeRx?
| 12-MAY-08: CeNeRx BioPharma Appoints Mahnaz Asgharnejad as Vice President of Clinical Development read full article here... |
| 22-JAN-08: CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima™ Using Innovative Brain Imaging Study read full article here... |